Innovotech Inc. has announced its intention to obtain a stock quotation in the United States on the OTCQB Venture Market, an over-the-counter venture market operated by OTC Markets. This strategic move aims to enhance the company's visibility to the investment community and make it more accessible to both retail and institutional investors in the United States, with the goal of increasing liquidity for its common shares.
The OTCQB quotation will operate in parallel with Innovotech's primary Canadian listing on the TSX Venture Exchange. According to the company, this quotation is not expected to impose additional material compliance or reporting requirements. As a foreign private issuer, Innovotech will continue to meet its existing primary market disclosure obligations through SEDAR+, which satisfy OTC market requirements under established foreign issuer exemptions. Companies seeking admission to the OTCQB must meet specific financial standards, maintain current reporting obligations, and undergo an annual verification and management certification process.
In conjunction with the OTCQB listing application, Innovotech will also apply for eligibility with the Depository Trust Company, which would enable simplified electronic clearing and settlement of its common shares for U.S. investors. This additional step would streamline the trading process and potentially make the company's shares more attractive to American market participants.
Innovotech Inc. is a Canadian boutique contract research organization specializing in advanced laboratory services and commercializing proprietary technologies. The company has established itself as a leader in biofilm science, providing expertise in antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions. Its services are supported by innovative methodologies and products, including the widely-used MBEC Assay® kit for high-throughput antimicrobial and antibiotic testing. The company serves clients across multiple sectors through its ISO-certified and GMP-accredited laboratories, which are designed to meet rigorous regulatory and scientific standards such as those of the U.S. Food and Drug Administration and Health Canada. More information about the company's services and technologies is available at https://www.innovotech.ca.
The company's forward-looking statements acknowledge potential risks and uncertainties that could affect actual results, including regulatory environment challenges, currency fluctuations, reliance on key customers, operating result variations, government policy changes, clinical trial progress and costs, strategic relationship dependencies, intellectual property protection concerns, and potential litigation exposure. The company notes that should these risks materialize or management assumptions prove inaccurate, actual results could vary materially from those anticipated.
The original announcement can be viewed on www.newmediawire.com. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of the release.
